Under construction – not a live service
Sign in

NCT05436509TerminatedPhase 1/2

CD19/79b Bi-specific CAR-T Cell Therapy

CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies

Source: ClinicalTrials.gov · Last updated 2 Nov 2026

Brief summary (registry, in English)

The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi-specific CAR-T cells and their persistency in patients.

Status (registry)
Terminated
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
60 (actual)
First submitted
22 Jun 2022
Start date
1 Jun 2026
Primary completion date
1 Jul 2026
Lead sponsor
Shenzhen Geno-Immune Medical Institute
NCT number
NCT05436509

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • under systemic steroid treatment within a week of the treatment.
  • prior failed CD19 and CD79b CAR-T treatment.

Other illness

  • accompanied with other active diseases and difficult to assess patient response.
  • bacterial, fungal, or viral infection, unable to control.
  • living with HIV.
  • active HBV or HCV infection.

Other

  • pregnant and nursing mothers.

Who the study is looking for

  • age older than 6 months.
  • malignant B cell surface expression of CD19 or CD79b molecules.
  • the KPS score over 80 points, and survival time is more than 1 month.
  • greater than Hgb 80 g/L.
  • no contraindications to blood cell collection.

Age in the registry: 6 months to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Shenzhen Geno-immune Medical InstituteShenzhenChinaUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.